Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals. Read why TAK stock is a hold.

Hernán’s appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based ...

Kenshi (Kenjustsu) vs Takeda (Shirai Ryu) Me Second Fight: 3:14 Takeda (Shirai Ryu) Me vs Shinnok (Imposter) Third Fight: ...

Volleyball coach and influencer Chijo Takeda teamed up with Ikaika Ohana Volleyball to host clinics in Richland over the ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

With every detail, the designers, Ishka Designs, created a portrait of their client in this New York apartment.

Takeda’s oral orexin agonist, oveporexton, met all goals in two Phase III narcolepsy Type 1 trials, significantly boosting ...